Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)

Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score

Event · Clinical / regulatory
Product
bosakitug (ATI-045)
Milestone
topline data
Indication
atopic dermatitis

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 16, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ACRS
Bearish
high confidence
Mentioned
$ACRS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ACRSBearishLow
01

Why it matters

The failure to meet primary and secondary endpoints is expected to depress the stock, though the company highlights continued pipeline activity and upcoming trials for other assets.

02

Market read

First disclosure of a missed primary endpoint for a biotech trial; likely triggers short‑term sell‑off in ACRS.

03

What to watch

The company is shifting focus to oral kinase inhibitors and a bispecific antibody, which could mitigate the negative impact.

Relevance 8/10Novelty 8/10Timing: same‑day filing

Background

Aclaris Therapeutics (NASDAQ: ACRS) is a clinical‑stage biopharma developing immuno‑inflammatory therapies. The ADMIRATION trial evaluated bosakitug (ATI‑045) in moderate‑to‑severe atopic dermatitis.

Company-level read

Ticker impact

$ACRSBearishHigh confidence
Context

Aclaris Therapeutics disclosed top‑line Phase 2 results showing its anti‑TSLP antibody bosakitug missed primary and secondary endpoints in atopic dermatitis.

Expected impact

downward pressure as investors price in the missed endpoints

Evidence & confidence

Phase‑2 failure is material for a clinical‑stage biotech; market typically reacts negatively to missed primary endpoints.

Market effects

May dampen sentiment for other atopic dermatitis and TSLP‑targeted programs.

Limited to US‑listed biotech sector.

Low; impact confined to niche immunology biotech space.

Counterpoint

Management emphasizes robust target engagement and pipeline progress, suggesting long‑term upside despite this setback.

Key entities

  • Aclaris Therapeutics, Inc.

    NASDAQ‑listed biotech reporting Phase 2 trial results.

  • Bosakitug (ATI‑045)

    Anti‑TSLP monoclonal antibody tested in atopic dermatitis.

Related articles

$ACRSMedAI 8/10

Wedbush cuts Aclaris Therapeutics stock rating on trial miss

Wedbush downgraded Aclaris Therapeutics (ACRS) to Neutral, cutting its price target to $3.00 from $8.00 after a Phase 2 trial failure. The stock is down 13% over the past week. Wedbush expects Aclaris to shift focus to eosinophilic esophagitis but notes growing competition. Other analysts have mixed views on ACRS's pipeline and potential.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.

$ACRSHighAI 8/10

Aclaris stock falls after atopic dermatitis trial fails

Aclaris Therapeutics (NASDAQ:ACRS) shares dropped 6% after its Phase 2 ADMIRATION trial for atopic dermatitis treatment failed to meet primary and secondary endpoints. The trial evaluated bosakitug (ATI-045), which showed target engagement but did not improve Eczema Area and Severity Index scores. The company remains focused on other treatments, including modzatinib (ATI-2138) for lichen planus, with a Phase 2b trial underway.

$ACRSHighAI 8/10

Aclaris Therapeutics’ mAb fails in Phase II eczema trial

Aclaris Therapeutics' Phase II trial of bosakitug for atopic dermatitis failed to meet primary and secondary endpoints, though the drug showed target engagement. The company remains focused on other treatments, including modzatinib and ATI-052. The atopic dermatitis market is projected to grow to $21.5bn by 2033, with key players like Sanofi and AbbVie.